Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Long-Term Deferred Tax: 2021-2024

Historic Long-Term Deferred Tax for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $3.2 million.

  • Autolus Therapeutics' Long-Term Deferred Tax fell 29.51% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 29.51%. This contributed to the annual value of $3.2 million for FY2024, which is 5.75% up from last year.
  • Per Autolus Therapeutics' latest filing, its Long-Term Deferred Tax stood at $3.2 million for FY2024, which was up 5.75% from $3.1 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Long-Term Deferred Tax peaked at $3.2 million during FY2024, and registered a low of $1.8 million during FY2021.
  • In the last 3 years, Autolus Therapeutics' Long-Term Deferred Tax had a median value of $3.1 million in 2023 and averaged $2.8 million.
  • Data for Autolus Therapeutics' Long-Term Deferred Tax shows a peak YoY soared of 47.54% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Long-Term Deferred Tax stood at $1.8 million in 2021, then grew by 13.69% to $2.1 million in 2022, then spiked by 47.54% to $3.1 million in 2023, then grew by 5.75% to $3.2 million in 2024.